Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion - 20/08/11
, Annegret Geipel, MD b, Friederike Schwarz a, Thomas Krämer, MD a, Niels Wessel, PhD c, Renaldo Faber, MD a
Reprints: Holger Stepan, MD, Department of Obstetrics and Gynecology, Philipp-Rosenthalstr 55, 04103 Leipzig, Germany.Résumé |
Objective |
Soluble endoglin (sEng) is increased dramatically in preeclampsia and acts synergistically with soluble fms-like tyrosine kinase 1 (sFlt1) to promote the preeclamptic phenotype. The aim of this study was to investigate whether the sEng increase was present already in second-trimester pregnancies with abnormal uterine perfusion and whether the pregnancy was at risk for preeclampsia.
Study Design |
This prospective study includes 77 second-trimester pregnant women with abnormal uterine perfusion. sEng and sFlt1 were measured with an enzyme-linked immunosorbent assay.
Results |
Adverse pregnancy outcome was associated with higher sEng levels in the second trimester. SEng was highest in those pregnancies with early-onset preeclampsia. Combined analysis of sEng and sFlt1 is able to predict early-onset preeclampsia with a sensitivity of 100% and a specificity of 93.3%.
Conclusion |
Elevated sEng levels are detectable in second-trimester pregnancies with abnormal uterine perfusion and subsequent pregnancy complications. The concurrent measurement of uterine perfusion and angiogenic factors allows a highly efficient prediction of early-onset preeclampsia.
Le texte complet de cet article est disponible en PDF.Key words : angiogenesis, preeclampsia, pregnancy, uterine perfusion
Plan
| Cite this article as: Stepan H, Geipel A, Schwarz F, Krämer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008;198:175.e1-175.e6. |
Vol 198 - N° 2
P. 175.e1-175.e6 - février 2008 Retour au numéro
Article précédent
- Maternal-Fetal Medicine Units Network Cesarean Registry: impact of shift change on cesarean complications
- Jennifer L. Bailit, Mark B. Landon, Yinglei Lai, Dwight J. Rouse, Catherine Y. Spong, Michael W. Varner, Atef H. Moawad, Hyagriv N. Simhan, Margaret Harper, Ronald J. Wapner, Yoram Sorokin, Menachem Miodovnik, Mary Jo O’Sullivan, Baha M. Sibai, Oded Langer, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network ⁎
- Acetaminophen use during pregnancy: effects on risk for congenital abnormalities
- Cristina Rebordosa, Manolis Kogevinas, Erzsébet Horváth-Puhó, Bente Nørgård, Maria Morales, Andrew E. Czeizel, Hendrik Vilstrup, Henrik T. Sørensen, Jørn Olsen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?